Solasodine

Solasodine is a potentially useful precursor for steroidal compounds and hormones with anticonvulsant and central nervous system depressant activities. (In Vitro) :Solasodine (90 μM; 2 days) treatment displays significant sprouting in P19 cells. Solasodine induces strong expression of the different neuronal markers studied, including βIII-tubulin, synaptophysin, MAP2, ChAT, and neuroblast marker doublecortin. Solasodine induces the differentiation of P19 cells, essentially towards the neuronal pathway. Solasodine induce apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins. (In Vivo) :Solasodine (25-100 mg/kg; intraperitoneal injection; once) treatment significantly delays latency of hind limb tonic extensor (HLTE) phase in the PCT-induced convulsions. And significantly potentiates Thiopental-provoked sleep in a dose-dependent manner. Solasodine has anticonvulsant and CNS depressant activities.Solasodine (375 μM; i.c.v.; for 2 weeks) treatment results a significant increase in bromodeoxyuridine uptake by cells of the ependymal layer, subventricular zone, and cortex that co-localized with doublecortin immunostaining. Solasodine treatment in rats results in a dramatic increase in expression of the cholesterol- and drug-binding translocator protein in ependymal cells.

126-17-0

Purapuridine | Solancarpidine | Solasodin

>98% (HPLC)

DMSO : 2.6 mg/mL 6.29 mM; H2O : < 0.1 mg/mL

C[C@]12CC[C@@H] (CC1=CC[C@@H]1[C@@H]2CC[C@@]2 (C) [C@H]1C[C@H]1[C@@H]2[C@@H] ([C@@]2 (CC[C@H] (CN2) C) O1) C) O

C27H43NO2

413.65

Storage temperature: -20°C. Stability: ≥ 2 years